Time to improvement in patient with paclitaxel -induced peripheral neurotoxicity in patients with breast cancer.

Time to improvement in patient with paclitaxel -induced peripheral neurotoxicity in patients with breast cancer. - Time to improvement in patient with paclitaxel -induced peripheral neurotoxicity in patients with breast cancer.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006306

Enrollment

100

Registered

2011-09-07

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)breast cancer patient scheduled for treatment with Paclitaxel or nab-Paclitaxel 2) age: >=20 3) ECOG performance status of 0 or 1 or 2 4)required baseline laboratory parameters 5)expected more than 6 months survival 6)written informed consent

Exclusion criteria

Exclusion criteria: 1)with severe complications (such as liver failure, renal failure, heart failure) 2)with history of allergy 3)with peripheral neuropathy for other cause (such as severe edema, diabetes, vitamin B12 deficiency) 4)doctor's decision not to be registered to this study

Design outcomes

Primary

Measure	Time frame
Time to improvement chemotherapy -induced peripheral neurotoxicity is evaluated with CTCAE v4.0, PNQ	—

Secondary

Measure	Time frame
Freguency, severity of peripheral neurotoxicity	—

Countries

Japan

Contacts

Public ContactTakashi Ishikawa

Yokohama City University Medical Center Breast and thyroid surgery

045-261-5656

Outcome results